Drug delivery via porous silicon: a focused patent review

This patent review article brought to MedChemNet users by our sister journal Pharmaceutical Patent Analyst, provides a patent review for drug delivery methods based on porous silicon.

Go to the profile of MedChemNet
May 16, 2017
0
0
Upvote 0 Comment

In this patent review, Paulina Kulyavtsev and Roxanne Spencer (Princeton International School of Mathematics & Science; Princeton, NJ, USA) explore the patenting activity for drug delivery methods based on porous silicon.

Although silicon is more commonly associated with computer chips than with drug delivery, with the discovery that porous silicon is a viable biocompatible material, mesoporous silicon with pores between 2 and 50 nm has been loaded with small molecule and biomolecule therapeutics and safely implanted for controlled release. As porous silicon is readily oxidized, porous silica must also be considered for drug delivery applications. Since 2010, only a limited number of US patents have been granted, primarily for ophthalmologic and immunotherapy applications, in contrast to the growing body of technical literature in this area.

Read the full article here:

Kulyavtsev PA, Spencer RP. Drug delivery via porous silicon: a focused patent review. Pharm. Pat. Anal. 6(2), 77-85 (2017)

Go to the profile of MedChemNet

MedChemNet

A network for the medicinal chemistry community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.